Overview

Telmisartan and Losartan in Hypertensive IGT

Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
0
Participant gender:
All
Summary
Inhibition of RAS delays onset of diabetes in clinical studies. Preliminary evidence suggests that telmisartan may have unique metabolic properties compared to other ARB due to activation of PPARĪ³. This should be tested in comparison with an ARB that is metabolically neutral in already published studies. H0: Telmisartan is not different from Losartan with respect to metabolic and vascular effects. H1: Telmisartan is different from Losartan with respect to metabolic and vascular effects.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical University of Graz
Treatments:
Losartan
Telmisartan
Criteria
Inclusion Criteria:

- IGT according the criteria of the WHO

- standardised office blood pressure > 140/90 mmHG or treated hypertension

- 40 - 75 years of age

- signed informed consent

Exclusion Criteria:

- known hypersensitivity towards telmisartan or losartan

- concommitant treatment with ACE-inhibitors

- BMI > 35 kg/m2

- inability to perform self-control of blood pressure

- acute coronary syndrome or cerebrovascular event within the last 3 months

- Revascularisation within the last 3 months

- heart failure > NYHA 2